Medications for Metastatic Melanoma

3 results

  • mektovi

    (BINIMETINIB)
    Array BioPharma Inc.
    MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in adult patients with BRAF V600E or V600K mutations, as identified by FDA-approved testing.

  • proleukin

    (aldesleukin)
    Clinigen Limited
    Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC) and metastatic melanoma.

  • tafinlar

    (dabrafenib)
    Novartis Pharmaceuticals Corporation
    TAFINLAR is indicated for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, non-small cell lung cancer, anaplastic thyroid cancer, solid tumors, and low-grade glioma in patients aged one year and older. It should not be used in colorectal cancer or wild-type BRAF tumors.